UNSPSC 51172313: Fomepizole

This classification denotes an enzyme inhibitor with the molecular formula C4H6N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 83LCM6L2BY, chemically known as 1h-pyrazole, 4-methyl- but generally known as fomepizole, which bears US NIH Compound Identifier 3406. European Medicines Agency schedules Fomepizole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07775MIG. The term FOMEPIZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31).

UNSPSC 51172313 Fomepizole is a Commodity code representing pharmaceutical products for clinical and correctional-facility use in state and local procurement. Recent solicitations show active demand for drug-testing services and multi-source generic pharmaceuticals distributed through established wholesale channels, though fomepizole itself appears in broader procurement aggregates rather than as a standalone line item.

State and local buyers soliciting under or adjacent to this code include county criminal-justice agencies, state health and human services departments, and multistate cooperative purchasing alliances. Collin County Community Supervision and Corrections Department (Texas) issued RFP 2026-327 on July 9, 2026, for offender specimen collection and drug testing services with a response deadline of July 23, 2026 and an estimated contract value of $600,000 over two years with three optional one-year renewal periods. The Texas Health and Human Services Commission posted Request for Information HHS0017013 on April 3, 2026, to gather market intelligence on direct-to-manufacturer prescription programs and therapeutic pharmacy initiatives. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products to serve participating state and local facilities across multiple jurisdictions including Oregon, with proposals due March 26, 2026.

Recent activity concentrates in Texas and Minnesota, with MMCAP's multistate cooperative structure extending reach across additional participating states. The code shows fragmented demand: criminal-justice corrections procurement focuses on testing services and ancillary protocols, while state health agencies and cooperative purchasing vehicles procure generic pharmaceuticals in volume through authorized wholesalers. Fomepizole—an antidote for methanol and ethylene glycol poisoning—likely enters state and local inventories through the generic pharmaceutical and OTC products channels represented in MMCAP's RFP rather than through emergency-response or poison-control standalone solicitations in the recent record.